ENVB logo

ENVERIC BIOSCIENCES INC

ENVBNASDAQ
🏆 #5432 by market capEarnings Nov 12US Equity
$252.13▼ $6.83 (−2.71%)
Simulated price
🔔
Track ENVB
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.7%
7d▲ 15857.6%
14d▲ 16821.5%
30d▲ 18038.8%
ytd▲ 6500.3%
1y▲ 3098.0%
🏦Market Cap
$877,608
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$249.19 – $255.67
52-Week Range
$1.17 – $13.25
Volume
$1.92B
Avg Volume
$1.98B
Shares Outstanding
597,012
Next Earnings
Oct 24, 2026

Fundamentals Snapshot

Annual Revenue
$56,988
Last Q Revenue
$13,174
P/E Ratio
-0.1
P/S Ratio
0.0x
EPS (TTM)
$-2.19
Dividend Yield
0.00%
Dilution (1yr)
+1845.0%

Why Investors Own ENVB

  • ✓High-growth profile — revenue up +35.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 39% gross margin and 20% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ENVB logo

ENVERIC BIOSCIENCES INC

ENVB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▼ −8.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$8M▲ +5.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.1M▲ +1845.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▲ +$2M YoY
StockOtter · stockotter.space

About ENVERIC BIOSCIENCES INC

Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$322.02
▲ +27.7% Upside
High Target$353.91
Low Target$254.98
Based on 10 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

ENVERIC BIOSCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift ENVB price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

ENVERIC BIOSCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.